Plain-English translation of NCT06245603 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a protective gel called Hydeal Cyst can help reduce uncomfortable side effects when used during standard bladder cancer treatment. People with early-stage bladder cancer who are already receiving chemotherapy or immunotherapy directly into the bladder will either receive the medication alone or receive the medication plus Hydeal Cyst instillations. The study wants to see if this gel makes the standard treatment easier to tolerate.
Standard bladder cancer treatments, while effective, can cause uncomfortable urinary symptoms and side effects. Researchers want to know if this protective gel can shield the bladder lining and reduce these side effects, making treatment more bearable for patients.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either receive the standard bladder medication alone or the standard medication plus Hydeal Cyst gel instillations. Both groups will receive weekly treatments through a catheter (a thin tube placed in the bladder) for 6 to 8 weeks. You'll have physical exams before each treatment, answer symptom questionnaires, and complete quality-of-life surveys to help researchers understand how you're feeling. The study involves about 200 patients total across the two treatment groups.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Italy
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.